Akorn (AKRX) Earning Somewhat Positive Press Coverage, Study Finds

Media headlines about Akorn (NASDAQ:AKRX) have trended somewhat positive on Thursday, Accern reports. The research firm ranks the sentiment of press coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Akorn earned a news impact score of 0.04 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.8086702146191 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Akorn (NASDAQ AKRX) opened at $31.75 on Thursday. Akorn has a 52-week low of $19.67 and a 52-week high of $34.00. The company has a debt-to-equity ratio of 0.92, a quick ratio of 3.17 and a current ratio of 4.16. The company has a market cap of $3,999.76, a P/E ratio of 32.07, a price-to-earnings-growth ratio of 1.65 and a beta of 1.33.

AKRX has been the topic of a number of recent research reports. BidaskClub upgraded shares of Akorn from a “strong sell” rating to a “sell” rating in a research report on Monday. Zacks Investment Research cut shares of Akorn from a “hold” rating to a “sell” rating in a research report on Wednesday, January 31st. Jefferies Group set a $34.00 price target on shares of Akorn and gave the company a “hold” rating in a research report on Sunday, October 29th. Finally, Piper Jaffray Companies set a $34.00 price target on shares of Akorn and gave the company a “hold” rating in a research report on Sunday, October 22nd. Three analysts have rated the stock with a sell rating and eight have issued a hold rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $29.17.

In other news, major shareholder John N. Kapoor sold 13,629 shares of the stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $32.67, for a total transaction of $445,259.43. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Brian Tambi sold 15,100 shares of the stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $33.35, for a total value of $503,585.00. The disclosure for this sale can be found here. Corporate insiders own 28.20% of the company’s stock.

WARNING: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this piece of content can be viewed at https://sportsperspectives.com/2018/02/08/akorn-akrx-earning-somewhat-positive-press-coverage-study-finds.html.

Akorn Company Profile

Akorn Inc (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two segments: Prescription Pharmaceuticals and the Consumer Health.

Insider Buying and Selling by Quarter for Akorn (NASDAQ:AKRX)

Receive News & Ratings for Akorn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akorn and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply